Stemming the Prescription drug abuse epidemic
Pain medications are essential for improving the care and outcomes for the 100 million adults living with chronic pain in the United States.
Ensysce Biosciences' proprietary abuse-resistant opioid prodrug technology – the TAAP platform - is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse.
The Multi-Pill Abuse Resistant (MPAR™) technology is unique to the industry and is designed not only to overcome abuse but to save lives.
TAAP abuse-resistant prodrugs and MPAR™ combination products have the potential to meet the medical needs of patients, while providing a solution to the national epidemic of prescription drug abuse.